Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol

被引：5
作者：
Asano, Tsuyoshi [1 ,2 ]
Shimizu, Tomohiro [1 ,2 ]
Takahashi, Daisuke [1 ,2 ]
Ota, Masahiro [1 ,2 ,3 ]
Sato, Dai [1 ,2 ,4 ]
Hamano, Hiroki [1 ,2 ]
Hiratsuka, Shigeto [1 ,2 ]
Takahata, Masahiko [1 ,2 ]
Iwasaki, Norimasa [1 ,2 ]
机构：
[1] Hokkaido Univ, Fac Med, Dept Orthopaed Surg, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan
[2] Hokkaido Univ, Grad Sch Med, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan
[3] Hokushokai Hosp, Dept Orthopaed Surg, Iwamizawa, Japan
[4] Iwamizawa City Hosp, Dept Orthopaed Surg, Iwamizawa, Japan
来源：
JOURNAL OF BONE AND MINERAL METABOLISM | 2019年 / 37卷 / 02期
关键词：
Postmenopausal osteoporosis; Denosumab; Hypocalcemia; Bene metabolic marker; Teriparatide; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; INDUCED HYPOCALCEMIA; TURNOVER; RISK; RISEDRONATE; ALENDRONATE; THERAPY; MARKERS;
D O I：
10.1007/s00774-018-0928-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The aims of this study are to investigate changes in serum calcium (Ca) level after switching from either non-therapy, bisphosphonate, selective estrogen receptor modulators (SERM) or teriparatide treatments to a combination therapy of denosumab (DMAb), and eldecalcitol, and the association between early changes in serum calcium and changes in bone metabolic markers and bone mineral density (BMD). 129 patients with postmenopausal osteoporosis (32 non-pretreatment, 50 bisphosphonates, 18 SERM, and 29 teriparatide) were recruited and switched to DMAb plus eldecalcitol. Serum calcium levels, bone metabolism markers, and BMD measurements of the lumbar spine and femoral neck were evaluated. All groups showed an increase in BMD 6months and 1year after DMAb administration compared to baseline via suppression of bone metabolism markers. The TPD group showed a significant decrease in serum calcium level 1week after the first injection of DMAb and eldecalcitol compared to baseline and the bisphosphonate group. Changes in serum calcium level from baseline to 1week after the first injection of DMAb trended to correlate with changes in bone metabolism markers and lumbar BMD. The risks of DMAb-induced hypocalcemia are different between starting and switching from bone resorption inhibitors and bone formation promoters. Therefore, appropriate assessment before administration of DMAb, including pretreatment therapy as well as serum Ca and bone metabolic markers will help identify the risk of hypocalcemia following DMAb in combination with eldecalcitol. Our findings also showed that early change in serum Ca level after DMAb initiation could potentially predict the efficacy for therapy reaction.
引用
收藏
页码：351 / 357
页数：7
相关论文
共 18 条
  • [1] Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
    Anastasilakis, Athanasios D.
    Toulis, Konstantinos A.
    Polyzos, Stergios A.
    Anastasilakis, Chrysostomos D.
    Makras, Polyzois
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2012, 8 : 295 - 306
  • [2] [Anonymous], 1997, OSTEOPOROSIS INT, V7, P1
  • [3] A single-dose study of denosumab in patients with various degrees of renal impairment
    Block, Geoffrey A.
    Bone, Henry G.
    Fang, Liang
    Lee, Edward
    Padhi, Desmond
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (07) : 1471 - 1479
  • [4] Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate
    Brown, J. P.
    Roux, C.
    Ho, P. R.
    Bolognese, M. A.
    Hall, J.
    Bone, H. G.
    Bonnick, S.
    van den Bergh, J. P.
    Ferreira, I.
    Dakin, P.
    Wagman, R. B.
    Recknor, C.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 (07) : 1953 - 1961
  • [5] Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/jbmr.080901, 10.1359/JBMR.0809010]
  • [6] Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in RA patients: response to Mokuda
    Ebina, K.
    Hashimoto, J.
    Shi, K.
    Kashii, M.
    Hirao, M.
    Yoshikawa, H.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2015, 26 (04) : 1445 - 1445
  • [7] Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure
    Farinola, N.
    Kanjanapan, Y.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 (11) : 1243 - 1246
  • [8] Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
    Ferrari, S.
    Adachi, J. D.
    Lippuner, K.
    Zapalowski, C.
    Miller, P. D.
    Reginster, J. -Y.
    Torring, O.
    Kendler, D. L.
    Daizadeh, N. S.
    Wang, A.
    O'Malley, C. D.
    Wagman, R. B.
    Libanati, C.
    Lewiecki, E. M.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2015, 26 (12) : 2763 - 2771
  • [9] High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
    Ishikawa, Koji
    Nagai, Takashi
    Sakamoto, Keizo
    Ohara, Kenji
    Eguro, Takeshi
    Ito, Hiroshi
    Toyoshima, Yoichi
    Kokaze, Akatsuki
    Toyone, Tomoaki
    Inagaki, Katsunori
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1831 - 1840
  • [10] An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
    Johnell, O.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 (12) : 1726 - 1733
12